DNA minor groove binders and tubuline inhibitors as antitumor agents

DNA Minor Groove Binders and Tubuline Inhibitors as Antitumor Agents

New Modulators of A3 and A2B Adenosine Receptors

DNA Minor Groove Binders: the sulphur analog of duocarmicycin SA and CC-1065

Agents Antitumorales que interaccionan con el surco menor del'ADN y inibitors de la Tubulina

DNA Minor Groove Binders and Tubuline Inhibitors as Antitumor Agents

VEGF and IL-8 regulation by cytotoxic drugs in human melanoma cells: molecular mechanism modulated by A2B and A3 adenosine receptors

Pharmacological characterization of novel allosteric enhancers of the A1 adenosine receptors

A3 ADENOSINE RECEPTORS MODULATE HYPOXIA-INDUCIBLE FACTOR-1ALPHA EXPRESSION IN HUMAN CANCER CELLS

Cytotoxic drugs regulate VEGF and IL-8 expression in human melanoma cells by A2A and A3 adenosine receptors.

MODULATION OF MMP-9 IN U87MG GLIOBLASTOMA CELLS BY A3 ADENOSINE RECEPTORS

L'ipossia inibisce l'apoptosi indotta da paclitaxel mediante fosforilazione di BAD dipendente dall'adenosina nelle cellule di glioblastoma.

Synthesis and biological characterization of [3H] 2-amino 4,5,6,7-tetrahydrobenzo(b)thiophen-3-yl-4-chloro phenyl methanone, the first radiolabeled adenosine A1 allosteric enhancer

Synthesis and biological evaluation of new 8-heterocyclic xanthine derivative as highly potent and selective human A2B adenosine receptor antagonist

5-heteroarylcarbamoylamino-pyrazolo-triazolo pyrimidines as hA3 adenosine receptor antagonists.

Recent developments in the field of A2B and A3 adenosine receptors antagonists

Pharmacology of AS-16; a novel and selective adenosine A2B receptor antagonist.

New 2-arylpyrazolo[4,3-c]quinoline derivates as potent and selective human A3 adenosine receptor antagonists

Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors

Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors